Cargando…

Tamoxifen, serum lipoproteins and cardiovascular risk.

The influence of tamoxifen on plasma lipids and lipoproteins was monitored in 46 postmenopausal and 8 premenopausal women treated for advanced breast cancer up till 6 months. Total cholesterol (total-C) did not significantly change. However, high density lipoprotein cholesterol (HDL-C) and the HDL-C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruning, P. F., Bonfrer, J. M., Hart, A. A., de Jong-Bakker, M., Linders, D., van Loon, J., Nooyen, W. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1988
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246799/ https://www.ncbi.nlm.nih.gov/pubmed/3207604

Ejemplares similares

Primary hypothyroidism in breast cancer patients with irradiated supraclavicular lymph nodes.
por: Bruning, P., et al.
Publicado: (1985)

Non-protein bound oestradiol, sex hormone binding globulin, breast cancer and breast cancer risk.
por: Bruning, P. F., et al.
Publicado: (1985)

Lipoprotein Metabolism Indicators Improve Cardiovascular Risk Prediction
por: van Schalkwijk, Daniël B., et al.
Publicado: (2014)

Low Serum Paraoxonase-1 Activity Associates with Incident Cardiovascular Disease Risk in Subjects with Concurrently High Levels of High-Density Lipoprotein Cholesterol and C-Reactive Protein
por: Corsetti, James P., et al.
Publicado: (2019)

Pretreatment tumour-antigen Ta-4 in serum of patients with squamous cell carcinoma of the uterine cervix.
por: Kenter, G., et al.
Publicado: (1987)

The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer
por: Kaas, R, et al.
Publicado: (2003)

The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis
por: Sahebkar, Amirhossein, et al.
Publicado: (2017)

Sex and Tamoxifen confound murine experimental studies in cardiovascular tissue engineering
por: Blum, Kevin M., et al.
Publicado: (2021)

Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)

Lipoprotein (a) and cardiovascular risk factors in children and adolescents
por: Palmeira, Ástrid Camêlo, et al.
Publicado: (2013)

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
por: Pistilli, Barbara, et al.
Publicado: (2020)

Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.
por: Bruning, P. F., et al.
Publicado: (1990)

Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells
por: Brüning, Ansgar, et al.
Publicado: (2010)

Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
por: Willeit, Peter, et al.
Publicado: (2020)

A case of tamoxifen-induced hypertriglyceridemia monitoring the changes in lipoprotein fractions over time
por: Isobe, Hayato, et al.
Publicado: (2021)

Low‐Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific
por: Cupido, Arjen J., et al.
Publicado: (2022)

Myocardial infarction risk and tamoxifen therapy for breast cancer
por: Geiger, A M, et al.
Publicado: (2005)

Lipoprotein(a): the underutilized risk factor for cardiovascular disease
por: Khan, TZ, et al.
Publicado: (2019)

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
por: Jager, Nynke GL, et al.
Publicado: (2013)

Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
por: Jones, A. L., et al.
Publicado: (1992)

The Precipitation of Serum Lipoproteins by Gelatin
por: Amenta, J. S., et al.
Publicado: (1960)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
por: Gjerde, Jennifer, et al.
Publicado: (2010)

Lipoprotein (a), an independent cardiovascular risk marker
por: Saeedi, Ramesh, et al.
Publicado: (2016)

Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen
por: Hussaarts, Koen G.A.M., et al.
Publicado: (2019)

Optimization of tamoxifen-induced gene regulation in cardiovascular research
por: Sukumaran, Abitha, et al.
Publicado: (2022)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Inactivation of Staphylococcal Phenol Soluble Modulins by Serum Lipoprotein Particles
por: Surewaard, Bas G. J., et al.
Publicado: (2012)

Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol
por: Lawler, Patrick R., et al.
Publicado: (2017)

Establishing a threshold to predict risk of cardiovascular disease from the serum triglyceride and high-density lipoprotein concentrations in persons with spinal cord injury
por: La Fountaine, Michael F., et al.
Publicado: (2018)

Lipoprotein(a) as a cardiovascular risk factor: current status
por: Nordestgaard, Børge G., et al.
Publicado: (2010)

The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019)

Profoundly Disturbed Lipoproteins in Cirrhotic Patients: Role of Lipoprotein-Z, a Hepatotoxic LDL-like Lipoprotein
por: van den Berg, Eline H., et al.
Publicado: (2022)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Tamoxifen metabolism: pharmacokinetic and in vitro study.
por: Etienne, M. C., et al.
Publicado: (1989)

Tamoxifen for women at high risk of breast cancer
por: Nazarali, Safia A, et al.
Publicado: (2014)

Postprandial Lipoproteins and Cardiovascular Disease Risk in Diabetes Mellitus
por: Enkhmaa, Byambaa, et al.
Publicado: (2010)

Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
por: Baratta, Francesco, et al.
Publicado: (2023)

Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Lipoprotein (a): A Novel Cardiovascular Risk Factor
por: Kozarova, Miriam, et al.
Publicado: (2023)

Use of antipsychotics with tamoxifen
por: Ghabi, H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4fhsp6k6hcscs76mgsliphiq7o